Nuedexta (Dextromethorphan HBr/Quinidine) Patent Expiration, LOE Window & CMS Spending

Nuedexta (Dextromethorphan HBr/Quinidine) by Otsuka Pharmaceutical: FDA Orange Book LOE 2026-08-13, 3 AB generics, $207.0M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorOtsuka Pharmaceutical
FDA Application & PathwayN021879 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2026-08-13
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors3
2024 CMS Total Public Spend$207.0M
2024 Medicare Part D Spend$173.0M
2024 Medicaid Spend$34.0M
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 17.9% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Otsuka Pharmaceutical across sibling Meru public-data platforms.